• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for type 2 diabetes

byQasim HussainiandDaniel Fisher
April 20, 2018
in Cardiology, Chronic Disease, Endocrinology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. SGLT-2 or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment.

2. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Excess mortality and cardiovascular comorbidity is a concern in patients with type 2 diabetes. Several agents including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors have emerged efficacious in improving diabetes control. The current study is a meta-analysis that compares the efficacy and safety profile of these drug classes. SGLT-2 inhibitors and GLP-1 agonists were associated with significantly lower all-cause mortality than control groups as well as lower mortality compared to DPP-4 inhibitors. When compared to control groups, GLP-1 agonists and SGLT-2 inhibitors also had lower cardiovascular mortality, while SGLT-2 inhibitors were also associated with lower heart failure and myocardial infarction events. GLP-1 agonists were associated with higher risk of adverse events leading to trial withdrawal than were SGLT-2 inhibitors or DPP-4 inhibitors.

Overall, the study suggests that SGLT-2 or GLP-1 agonists are associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment. Some limitations of the study include clinical efficacy and safety evaluation by drug class instead of individual drug type and possible error introduced by participant characteristics that may affect relative efficacy for each drug class. The study also does not address the effect of the treatments on HbA1c and glycemic control. Future directions may include comparison against commonly prescribed metformin monotherapy.

Click to read the study, published in JAMA

Relevant Reading: Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

RELATED REPORTS

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

Meta-analysis shows significant decrease in age-related macular degeneration risk with metformin use

Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population

In-Depth [meta-analysis]: The current study is a meta-analysis that utilized a systematic search of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). Eligible trials (criteria in article) were extracted and reviewed, and the primary outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, heart failure events, myocardial infarction, unstable angina, and stroke. Safety end points were any adverse events, hypoglycemia, as well as additional drug-class specific adverse events. Overall, 236 trials were analyzed that randomized 176,310 participants. SGLT-2 inhibitors (-1.0% absolute risk difference) and GLP-1 agonists (absolute RD -0.6%) were associated with significantly lower all-cause mortality than control groups. SGLT-2 (absolute RD -0.9%) and GLP-1 agonists (absolute RD, -0.5%) also had lower mortality compared to DPP-4 inhibitors. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment. When compared to control groups, SGLT-2 inhibitors (absolute RD, -0.8%) and GLP-1 agonists (absolute RD, -0.5%) also had lower cardiovascular mortality, and SGLT-2 inhibitors were associated with lower heart failure (absolute RD, -1.1%) and myocardial infarction (absolute RD, -0.6%) events. GLP-1 agonists were also associated with higher risk of adverse events leading to trial withdrawal than were SGLT-2 inhibitors (absolute RD, 5.8%) or DPP-4 inhibitors (absolute RD, 3.1%).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular riskdiabetes mellitus
Previous Post

Intensive LDL-C lowering reduces mortality in patients with higher baseline LDL-C

Next Post

Teens’ e-cigarette use independently linked to future marijuana use

RelatedReports

Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Antioxidants, omega-3 lack benefit in age-related macular degeneration
Ophthalmology

Meta-analysis shows significant decrease in age-related macular degeneration risk with metformin use

December 19, 2022
UTI associated with increased risk of preeclampsia
Cardiology

Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population

December 13, 2022
Cardiology

Pemafibrate does not lower cardiovascular risk in individuals with hypertriglyceridemia

December 2, 2022
Next Post

Teens’ e-cigarette use independently linked to future marijuana use

Differences in sudden unexpected infant death rates reported between states

Prediction tool for urinary tract infections in preverbal children

Prevalence of hypertension among adolescents varies by race and BMI

Smartphone medication adherence application did not improve systolic blood pressure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options